Healthcare Business Report: Pfizer’s Top Line Data, BioSante Merges With ANI

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pfizer (NYSE:PFE) announces new top-line data showing that its Prevenar 13 conjugate vaccine in adults between 18 and 49 years of age met the primary objective for all 13 stereotypes. The firm says that the data support its recent European Commission regulatory filing and intends to back further regulatory submissions applying to the age group.

BioSante Pharmaceuticals (NASDAQ:BPAX) merges with ANI Pharmaceuticals in an all-stock transaction with BioSante being the surviving entity. Upon the conclusion, former BioSante shareholders will own approximately 47 percent.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

StemCells (NASDAQ:STEM) announces an initial transplant of neural cells into a patient in its evaluation of dry age-related macular degeneration in Dallas.

Shares of Neuralstem (AMEX:CUR) jump in a big way on word that the company will provide an update on the Phase I Neuralstem ALS trial of its human spinal cord stem cells, NSI-566, in the treatment of Lou Gehrig’s disease. The report will be presented by its principal investigator at the American Neurological Association annual meeting on October 8th.

Don’t Miss: Here’s Why NuVasive Came Crashing Down.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business